Objective: We measured serum NT-proBNP levels in 2 groups of young patients (0-36 months) with congestive heart failure (CHF) secondary to congenital heart malformations (CHM).
B-type natiuretic peptide (BNP) has been established as a biomarker of congestive heart failure (CHF). BNP is derived from compensatory neurohumoral activation of the myocardium. 1 The plasma concentrations of BNP change in response to excessive stretching of the myocardium that occurs in heart failure. The hormone is synthesized as pre-proBNP, which is enzymatically shortened to proBNP and then cleaved into 2 fragments: the active BNP hormone, and an inactive fragment, NTproBNP. 2 In healthy children, plasma natriuretic peptide levels increase during the first days of life. Then, they progressively decrease and are relatively constant throughout childhood. 3 Children with congenital heart malformations (CHM) with significant increases in heart cavity volume or pressure have high levels of these neurohormones, which are inversely proportional to functional capacity. 4, 5 In pediatric studies on natriuretic peptides have produced partial and equivocal results. 6 In adults, preoperative NT-proBNP levels provide prognostic information on postoperative risk, mortality, duration of hospitalization, and complications after heart surgery. [7] [8] [9] In children, studies have demonstrated an increase in serum BNP and NT-proBNP concentrations in the first week after heart surgery. [10] [11] [12] In children with heart transplantation, BNP significantly increases if rejection occurs. 13, 14 Our study had the following objectives: 1) To determine serum NT-proBNP levels in young children (0-3 years) with unoperated CHM; 2) To assess cardiomyocyte injury and cardiac dysfunction based on serum NT-proBNP levels in children with CHM within 24 hours after surgery; 3) To assess serum NT-proBNP levels in children with CHF secondary to CHM in two age groups, 0-12 months and 12-36 months. 
Materials and Methods

Patients
Two groups of children with CHF secondary to CHM were studied. The first study group included 23 patients with unoperated CHM, with Ross/NYHA (New York Heart Association) class II or III congestive heart failure. The second study group included 12 patients with CHM within 24 hours post-operation. Prior to surgery, the 12 patients also had a functional Ross/NYHA II or III score. All subjects were between 0-36 months old. The control group included 16 patients with normal cardiac function and with no other acute or chronic disease, between 0-36 months old. The study was approved by the local ethics board of Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania and informed consent of family members was obtained.
We selected these groups of patients because preoperative patient preparation required a significant amount of time. Therefore, we analyzed a larger number of patients pre-operatively. However, these patients were put on a waiting list to have surgery at a later date. The functional evaluation of pediatric CHF was based on Ross/ NYHA classes adapted to children. This classification system includes growth failure as an indicator of CHF in children. Ross classes are defined as follows: Class I, asymptomatic; class II, moderate tachypnea or diaphoresis during breast feeding, exertional dyspnea in older children; class III, marked tachypnea or diaphoresis during breastfeeding, prolonged breastfeeding, growth retardation due to CHF, or intense exertional dyspnea in older children; class IV, tachypnea, retractions, dyspnea, or diaphoresis at rest.
Methods
NT-proBNP levels were measured by an enzyme-linked immunosorbent immunoassay (ELISA) using the Chem Well 2910 (Awareness Technology Inc., Palm City, USA) automated analyzer. Lipemic and hemolyzed samples were avoided during testing and the serum samples were processed within 1 hour after testing. The results were validated using quality controls. The tests were provided by DRG Diagnostics Inc. (Marburg, Germany).
The performance characteristics of the ELISA method, provided by the manufacturer, were: Median 39.2 pg/mL (n=66), each laboratory should establish its own normal values; linear range 0-5237 pg/mL; specimen volume 50 μL; detection limit (0 pg / mL + 3 SD) 24.5 pg/mL and incubation time 3 hours/30 minutes.
Statistical Analysis
The differences in serum NT-proBNP levels between the groups were anayzed using the Kruskal Wallis and Mann-Whitney tests, because NT-proBNP values were not Gaussian distributed (Shapiro-Wilk test). The results of the Kruskal Wallis test for which P <0.05 were accepted as significant. In the case of the Mann-Whitney test, a Bonferroni correction was used, with a 0.02 level of significance.
Results
Clinical Data Analysis
Of the patients in group 1 with unoperated CHM, 12 were assigned to functional Ross/NYHA class II and 11 were assigned to functional Ross/NYHA class III ( Table 1) . Of the patients in group 2 with CHM within 24 hours postoperation, 4 were assigned to functional Ross/NYHA class II and 8 were assigned to functional Ross/NYHA class III ( Table 2 ). The age mean±SD (median) was 13.2 ± 9.8 (11.0) months and 7.2 ± 6.7 (4.0) months in patients with unoperated CHM and patients with CHM within 24 hours post-operation, respectively. No statistically significant differences were found regarding the age of the 2 groups (P =0.05>0.02).
Laboratory Data Analysis
The medians of NT-proBNP values were 382, 1350, and 90.8 in patients with unoperated CHM, patients with CHM within 24 hours post-operation, and controls, respectively (Table 3) .
Statistically significant differences in NT-proBNP values were found between the control group and the group of patients with unoperated CHM (Kruskal-Wallis test, P <0.001). Using a Bonferroni correction, with a 0.02 significance level, statistically significant differences in NTproBNP values were found between the control group and the group of patients with unoperated CHM (Mann-Whitney Science Analysis of serum NT-proBNP levels depends on age: The mean NT-proBNP value for the 0-12 months age group (16 patients) is 433.5 pg/mL compared to controls, 41 pg/mL; the mean NT-proBNP value for the 12-36 months age group (7 patients) is 277 pg/mL compared to controls, 93 pg/mL.
Discussion
Congestive heart failure occurs in childhood and is associated with high costs for therapy and diagnosis. Pathophysiological mechanisms of CHF in children include uncorrected cardiac defects, palliatively operated CHM, or postoperative complications; more than 50% of these patients develop heart failure, which is in accordance with our findings. We found high serum NT-proBNP levels in young children with unoperated CHM. However, the highest NT-pro BNP levels were found within 24 hours after heart surgery for the correction of CHM, which suggests that as cardiac dysfunction worsens, there is severe cardiomyocyte injury immediately postoperatively, or both. Another explanation for this observation is that in the study group there were more subjects with heart failure NYHA III than in the group patients with unoperated CHM.
Our results indicate the need for careful assessment of specific cardiotonic, diuretic, and vasodilator medications in the early postoperative period. It also confirms the need for sustained clinical and paraclinical monitoring until natriuretic peptide levels return to normal. These findings reveal the importance of these factors in young children (0-3 years), in whom the clinical and echocardiographic criteria for monitoring the evolution of heart failure, and particularly postoperative cardiac dysfunction, are subjective (clinical criteria) and difficult to obtain (echocardiographic parameters of ventricular function). Thus, measurement of serum NT-proBNP levels in these patients may provide an objective criterion for monitoring CHF, and for evaluating the postoperative status of the myocardium.
Ekure et al, 15 using a point-of-care analyzer, measured NT-proBNP in a group of 28 children with heart failure; the NT-proBNP mean value of 377 pg/mL in their study group was higher but very close to that of the control group, at mean value of 353 pg/mL. Nevo et al, 16 used an electrochemiluminescence immunoassay to measureNT-proBNP levels in children with noncardiac disease (292 pg/mL, n=138) and compared those results to healthy children (109 pg/mL, n=59) and patients with acute cardiac disease (50 pg/mL, n=30). Perez-Piaya et al, why so many different values have been reported for NT-proBNP (355 pg/mL in Ekure's study, 109 pg/ mL in Nevo's study, and 148 pg/mL in our study). Plasma natriuretic peptide concentrations are normally high during the first days of life and then decrease, remaining relatively constant during childhood. 18 High serum NT-pro BNP levels can be used for risk stratification in heart disease, along with systemic diseases such as thalassemia, cystic fibrosis, and sepsis. 19 Recent studies have revealed that plasma BNP levels are increased in children with heart disease before treatment, and are useful for monitoring the effectiveness of treatment.
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Conclusion
In subjects aged 0-3 years with CHM, the median NTproBNP value, determined by ELISA, was 4 times higher in patients with unoperated CHM without pre-operative preparation compared to controls (P <0.001). NT-proBNP values are 20 times higher in patients with CHM within 24 hours post-operation compared to controls (P <0.0001). The median NT-proBNP value for subjects with heart failure (433.5 pg/mL) aged between 0-12 months tends to be higher than in those aged between 12-36 months (277 pg/mL). LM
